Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. HCAT
HCAT logo

HCAT Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.950
Open
1.800
VWAP
1.88
Vol
9.17M
Mkt Cap
130.79M
Low
1.790
Amount
17.24M
EV/EBITDA(TTM)
8.16
Total Shares
73.89M
EV
171.64M
EV/OCF(TTM)
9.05
P/S(TTM)
0.40
Health Catalyst, Inc. is a provider of data and analytics technology and services to healthcare organizations. The Company's solution comprises its cloud-based data platform, applications, and expertise. Its segments include Technology and Professional Services. The Technology segment includes its data platform, analytics applications and support services and earns primarily from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees. The Professional Services segment is generally a combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver capabilities to its clients to fully configure and utilize the benefits of its technology offerings. Its clients, which are primarily healthcare providers, use its Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements.
Show More

Events Timeline

(ET)
2026-06-04
09:10:00
Health Catalyst Divests Vitalware to Med-Metrix for $147M
select
2026-05-11 (ET)
2026-05-11
16:50:00
Sees FY26 Adjusted EBITDA of $30M-$33M
select
2026-05-11
16:50:00
Sees Q2 Adjusted EBITDA of $9M-$10M
select
2026-05-11
16:40:00
Health Catalyst Q1 Revenue $70.76M Exceeds Expectations
select
2026-04-27 (ET)
2026-04-27
09:20:00
Health Catalyst Executive Linda Llewelyn to Depart on June 1, 2026
select
2026-04-27
09:10:00
Company Plans 9% Workforce Reduction by 2026
select

News

NASDAQ.COM
9.5
06-19NASDAQ.COM
Outset Medical Shares Surge 25.6% on HCA Deal
  • Significant Price Surge: Outset Medical's shares soared 25.6% in the last trading session to close at $5.05, with trading volume significantly exceeding normal levels, reflecting investor optimism about the company's future prospects.
  • Key Contract Signing: The company entered into a Refresh Amendment to its Purchasing Agreement with HCA Management Services, which will purchase new Tablo Hemodialysis Systems from 2026 to 2028 for an aggregate value of approximately $40 million, providing a stable revenue stream for the company.
  • Earnings Report Expectations: Outset Medical is expected to report a quarterly loss of $0.63 per share, representing a year-over-year change of +25%, while revenues are projected at $28.8 million, down 8.3% from the previous year, yet the market remains optimistic about future growth potential.
  • Market Performance Analysis: Although the current EPS estimates have remained unchanged over the past 30 days, the stock's price increase is typically correlated with trends in earnings estimates, prompting investors to monitor Outset Medical's future earnings trends to assess the sustainability of its stock price increase.
Yahoo Finance
2.0
06-17Yahoo Finance
Analysis of Falling Shares of Health Catalyst and Paycom
  • Market Volatility Impact: Health Catalyst (HCAT) shares fell 3.6% and Paycom (PAYC) dropped 3.5% as investors rotated from high-multiple growth stocks to cyclicals, indicating a cautious market sentiment towards tech stocks amid rising inflation data.
  • Inflation Data Shock: May import prices rose by 1.9%, significantly above the 1.1% forecast, with an annual increase of 6.7%, the largest since August 2022, exacerbating concerns about future interest rate hikes and impacting software company valuations.
  • AI Bubble Risk: A Bank of America fund manager survey revealed that 28% of respondents view the AI bubble as the second-largest tail risk, prompting portfolio managers to reduce allocations to tech stocks, which adds further pressure on companies like Health Catalyst and Paycom.
  • Poor Long-term Performance: Health Catalyst has declined 23% year-to-date, trading at $1.76, which is 57.1% below its 52-week high of $4.09, reflecting diminished investor confidence in its future cash flows and a broader pessimistic sentiment towards the software sector.
Newsfilter
1.0
06-16Newsfilter
Health Catalyst to Participate in Healthcare Disruptors Conference
  • Executive Participation: Health Catalyst's senior management will participate in the Truist Securities Healthcare Disruptors & Digital Health Conference, with CEO Ben Albert leading a panel discussion on 'AI ROI in Healthcare: Real vs Hype' on June 24, 2026, at 3:30 PM, showcasing the company's leadership in the industry.
  • Technology-Driven Outcomes: Leveraging proprietary AI-driven technology, Health Catalyst has documented $2.8 billion in outcomes, assisting health systems in achieving measurable improvements across cost, clinical, and consumer performance, thereby solidifying its competitive edge in the market.
  • Industry Influence: By engaging in significant industry conferences, Health Catalyst not only demonstrates its expertise in healthcare intelligence but also provides attendees with profound insights on leveraging AI technology to enhance healthcare efficiency, driving industry innovation.
  • Strengthening Investor Relations: This conference offers Health Catalyst an opportunity to interact with investors and industry leaders, further enhancing its influence in the healthcare sector and laying the groundwork for future strategic collaborations.
NASDAQ.COM
8.5
06-05NASDAQ.COM
Veru Shares Surge 88% on Novo Nordisk Collaboration
  • Veru Stock Surge: Shares of Veru Inc. (VERU) soared 88% on Thursday following a clinical supply agreement with Novo Nordisk, which involves a Phase 2b trial of its lead drug Enobosarm, potentially enhancing the company's market position in obesity treatment significantly.
  • Clinical Trial Details: The PLATEAU trial will assess the effects of Enobosarm on total body weight and bone density in approximately 200 older patients with obesity, with Novo Nordisk providing Wegovy at no cost to ensure the trial's success.
  • Health Catalyst Strategic Shift: Health Catalyst Inc. (HCAT) closed at $1.94, up 45.86%, as its subsidiary Vitalware was acquired by Med-Metrix, marking a new phase for the company and expected to strengthen its competitive edge in healthcare data analytics.
  • Absci Clinical Progress: Absci Corp. (ABSI) shares rose 23.57% as the company advances its AI-designed antibody ABS-201 in clinical trials, with preliminary safety data expected in 2026, which could propel its growth in the biopharmaceutical sector.
NASDAQ.COM
8.5
06-04NASDAQ.COM
Med-Metrix Acquires Vitalware to Enhance Technology Platform
  • Acquisition Agreement: Med-Metrix has entered into a definitive agreement to acquire Vitalware from Health Catalyst, which is expected to enhance Med-Metrix's technology platform and improve reimbursement accuracy and net revenue yield for its clients.
  • Integration Benefits: The leadership team and employees of Vitalware will be integrated into Med-Metrix's operations, enhancing the company's ability to deliver end-to-end revenue cycle management solutions by combining differentiated technology with operational expertise.
  • Industry Impact: Founded in 2011, Vitalware's cloud-based solutions have been widely adopted across hospitals and health systems, improving visibility and continuity in billing and coding processes, thereby enhancing client satisfaction.
  • Financial Outcome Expectations: Med-Metrix executives highlighted that the acquisition will help providers identify revenue leakage, strengthen compliance, and optimize net patient revenue, further enhancing the company's competitive position in the healthcare revenue cycle management sector.
PRnewswire
8.5
06-04PRnewswire
Med-Metrix Acquires Vitalware to Enhance Revenue Management
  • Acquisition Overview: Med-Metrix has entered into a definitive agreement to acquire Vitalware, a leader in revenue workflow and analytics software owned by Health Catalyst, which is expected to significantly enhance Med-Metrix's mid-revenue cycle capabilities and improve net revenue yield for its clients.
  • Technological Integration Benefits: Vitalware's cloud-based solutions excel in chargemaster management, revenue integrity, and coding workflows, and by integrating this technology, Med-Metrix will better support its expanding health system client base in identifying revenue leakage and optimizing net patient revenue.
  • Leadership Team Integration: Following the acquisition, Vitalware's leadership team and employees will be integrated into Med-Metrix's operations, which will not only enhance the company's operational capabilities but also improve its ability to deliver end-to-end solutions, driving further business growth.
  • Strategic Investment Context: Supported by Harvest Partners and A&M Capital Partners, this acquisition reflects confidence in Med-Metrix's future growth strategy, with Vitalware's addition providing stronger market competitiveness and technological support to aid its continued expansion in the healthcare services sector.
Wall Street analysts forecast HCAT stock price to rise
7 Analyst Rating
Wall Street analysts forecast HCAT stock price to rise
3 Buy
4 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
2.75
Averages
3.85
High
5.00
Current: 0.000
sliders
Low
2.75
Averages
3.85
High
5.00
Wells Fargo
Stan Berenshteyn
Equal Weight
maintain
$1
AI Analysis
2026-06-26
New
Reason
Wells Fargo
Stan Berenshteyn
Price Target
$1
AI Analysis
2026-06-26
New
maintain
Equal Weight
Reason
Wells Fargo analyst Stan Berenshteyn raised the firm's price target on Health Catalyst to $1.75 from $1 and keeps an Equal Weight rating on the shares to account for the pending Vitalware sale.
Stephens
Equal Weight
downgrade
$2
2026-05-12
Reason
Stephens
Price Target
$2
2026-05-12
downgrade
Equal Weight
Reason
Stephens lowered the firm's price target on Health Catalyst to $1.75 from $2 and keeps an Equal Weight rating on the shares. The combination of better-than-expected Q1 and below-consensus FY26 guidance yield a lower-than-anticipated exit rate that will drive down revenue estimates for FY26 and FY27, the analyst tells investors.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for HCAT
Unlock Now

Valuation Metrics

The current forward P/E ratio for Health Catalyst Inc (HCAT.O) is 7.76, compared to its 5-year average forward P/E of -15.44. For a more detailed relative valuation and DCF analysis to assess Health Catalyst Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-15.44
Current PE
7.76
Overvalued PE
97.72
Undervalued PE
-128.59

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-69.87
Current EV/EBITDA
8.89
Overvalued EV/EBITDA
86.36
Undervalued EV/EBITDA
-226.09

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.51
Current PS
0.52
Overvalued PS
5.08
Undervalued PS
-0.06

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what compainies should i look at
Intellectia · 87 candidates
Market Cap: <= 2.00BRegion: USPrice: <= $5.00Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA5, PriceCrossAboveMA5Week Price Change Pct: >= $0.00One Week Predict Return: >= 0.0%
Ticker
Name
Market Cap$
top bottom
LASE logo
LASE
Laser Photonics Corp
119.56M
HCAT logo
HCAT
Health Catalyst Inc
142.62M
NWL logo
NWL
Newell Brands Inc
1.58B
DLTH logo
DLTH
Duluth Holdings Inc
126.59M
MYO logo
MYO
Myomo Inc
49.46M
CALC logo
CALC
CalciMedica Inc
16.75M
good penny stocks soon to blow up
Intellectia · 26 candidates
Market Cap: <= 300.00MPrice: $0.50 - $5.00Volume: >= 500,000Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20, PriceAboveMA60, PriceCrossAboveMA20
Ticker
Name
Market Cap$
top bottom
VVOS logo
VVOS
Vivos Therapeutics Inc
12.01M
ELOG logo
ELOG
Eastern International Ltd
15.53M
BCDA logo
BCDA
BioCardia Inc
11.72M
YXT logo
YXT
YXT.Com Group Holding Ltd
32.36M
SCAG logo
SCAG
Scage Future
61.22M
GLXG logo
GLXG
Galaxy Payroll Group Ltd
6.62M
stocks to buy 20 to 1 $ which can i buy now
Intellectia · 413 candidates
Price: $1.00 - $20.00Weekly Average Turnover: >= 1,000,000Moving Average Relationship: PriceAboveMA5
Ticker
Name
Market Cap$
top bottom
GERN logo
GERN
Geron Corp
855.40M
CGTX logo
CGTX
Cognition Therapeutics Inc
125.35M
PZG logo
PZG
Paramount Gold Nevada Corp
112.84M
OSTX logo
OSTX
OS Therapies Inc
52.82M
GNLN logo
GNLN
Greenlane Holdings Inc
12.83M
LAB logo
LAB
Standard BioTools Inc
630.69M
What penny stock will go up this week
Intellectia · 23 candidates
Market Cap: <= 2.00BPrice: <= $5.00Relative Vol: >= 1.10Beta: HighRiskWeek Price Change Pct: $-5.00 - $0.00
Ticker
Name
Market Cap$
top bottom
EVGO logo
EVGO
EVgo Inc
951.67M
INDI logo
INDI
indie Semiconductor Inc
933.44M
IHRT logo
IHRT
iHeartMedia Inc
566.10M
GETY logo
GETY
Getty Images Holdings Inc
528.14M
GEVO logo
GEVO
Gevo Inc
487.04M
CLNE logo
CLNE
Clean Energy Fuels Corp
486.85M

Whales Holding HCAT

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Health Catalyst Inc (HCAT) stock price today?

The current price of HCAT is 1.9 USD — it has increased 7.34

What is Health Catalyst Inc (HCAT)'s business?

Health Catalyst, Inc. is a provider of data and analytics technology and services to healthcare organizations. The Company's solution comprises its cloud-based data platform, applications, and expertise. Its segments include Technology and Professional Services. The Technology segment includes its data platform, analytics applications and support services and earns primarily from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees. The Professional Services segment is generally a combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver capabilities to its clients to fully configure and utilize the benefits of its technology offerings. Its clients, which are primarily healthcare providers, use its Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements.

What is the price predicton of HCAT Stock?

Wall Street analysts forecast HCAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HCAT is3.85 USD with a low forecast of 2.75 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Health Catalyst Inc (HCAT)'s revenue for the last quarter?

Health Catalyst Inc revenue for the last quarter amounts to 70.76M USD, decreased -10.90

What is Health Catalyst Inc (HCAT)'s earnings per share (EPS) for the last quarter?

Health Catalyst Inc. EPS for the last quarter amounts to -1.53 USD, increased 337.14

How many employees does Health Catalyst Inc (HCAT). have?

Health Catalyst Inc (HCAT) has 1300 emplpoyees as of June 26 2026.

What is Health Catalyst Inc (HCAT) market cap?

Today HCAT has the market capitalization of 130.79M USD.